Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a transmembrane immunoreceptor primarily expressed by microglia and other myeloid-lineage cells. Through association with the adaptor protein DAP12, TREM2 activates SYK-, PI3K-, and MAPK-dependent signaling pathways that regulate microglial survival, lipid metabolism, and phagocytic function. Pathogenic TREM2 variants, such as R47H, significantly increase the risk of Alzheimer’s disease and other neurodegenerative disorders by impairing microglial recognition and clearance of amyloid-β and tau aggregates. In addition to its membrane-bound form, soluble TREM2 (sTREM2) is released into cerebrospinal fluid and plasma, where it serves as a promising biomarker of microglial activation, neuroinflammation, and disease progression. Catalina’s rigorously validated TREM2 antibodies provide exceptional specificity and sensitivity for investigating TREM2 biology, signaling mechanisms, and biomarker dynamics in neurodegeneration and translational neuroscience research.